Published in Ann Intern Med on December 01, 1979
Breast cancer and thoracic metastases: review of 119 patients. Thorax (1983) 1.04
Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) (1983) 0.89
Adjuvant chemotherapy for early breast cancer. Br Med J (Clin Res Ed) (1983) 0.75
The effect of surveillance on the outcome of breast cancer patients. Iran J Cancer Prev (2013) 0.75
Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Breast Cancer Res Treat (1991) 0.75
Statistical methods for the identification and use of prognostic factors. Int J Cancer (1974) 11.07
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
A note on quantifying follow-up in studies of failure time. Control Clin Trials (1996) 7.96
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol (1995) 5.36
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg (1978) 4.55
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Estimation of human body surface area from height and weight. Cancer Chemother Rep (1970) 4.17
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
OSM-9, a novel protein with structural similarity to channels, is required for olfaction, mechanosensation, and olfactory adaptation in Caenorhabditis elegans. J Neurosci (1997) 4.06
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer (1988) 3.29
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer (1995) 3.11
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch Gen Psychiatry (1996) 3.02
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol Aging (2001) 2.85
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85
Estimating survival functions from the life table. J Chronic Dis (1969) 2.83
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
The Intergroup Rhabdomyosarcoma Study-II. Cancer (1993) 2.77
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol (1990) 2.70
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol (2001) 2.56
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Reliability of measurements of muscle tone and muscle power in stroke patients. Age Ageing (2000) 2.49
Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol (1990) 2.48
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol (2002) 2.42
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Carcinoma of the male breast. Ann Intern Med (1992) 2.27
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15